April 15, 2022
2021 Annual Report: CEO Yvonne Greenstreet Reflects on an Important Year in the RNAi Revol ...
In conjunction with the publishing of Alnylam's 2021 Annual Report, Alnylam's CEO Yvonne Greenstreet reflects on the year that was...
Read More ›
October 1, 2020
A New European Biotech Social Pact
The European Pact builds on Alnylam’s own pledge, encouraging biotech companies to be a force for good in partnering with European authorities, citizens and...
Read More ›
September 10, 2020
Brendan Martin on the Pharmaphorum Podcast
Alnylam’s Brendan Martin, Head of Europe, Middle East, Africa, and Canada and General Manager for the UK & Ireland, recently spoke on the Pharmaphorum podcast.
Read More ›
September 2, 2020
With Innovation in Market Access, European Patients Can Fully Experience Biotech’s Transfo ...
What’s needed is a larger measure of creativity, flexibility and coordination around market access. This must become the new baseline environment in which...
Read More ›
April 11, 2019
Letter to the Editor: Federal Research is Important, but Companies Turn it Into Actual Tre ...
John Maraganore wrote a Letter to the Editor in The Washington Post about the importance of federal research...
Read More ›
January 3, 2019
John Maraganore Talks RNAi on Chemical & Engineering News Podcast
John Maraganore talks with Chemical & Engineering News' Lisa Jarvis and Ryan Cross on this episode of C&EN's Stereo Chemistry podcast.
Read More ›
May 9, 2018
First Rounders: John Maraganore
Our CEO John Maraganore, Ph.D. recently chatted with the Nature Biotechnology Podcast about his path into science, through research and ultimately into biotech.
Read More ›
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site